Onderzoeker
Elisa Ardizzoni
Affiliaties
- Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf1 mrt 2009 → Heden - Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf28 feb 2009 → 16 apr 2015
Projecten
1 - 7 of 7
- TB/NTM OnderzoeksclusterVanaf1 jan 2022 → Heden
- EndTB-Q Output 5 testing new regimens to treat MDR-TB resistant to fluoroquinilonesVanaf1 jul 2020 → Heden
- MSF Routine ServicesVanaf1 mrt 2020 → 28 feb 2024
- Effectiveness and tolerability of a short regimen for drug resistant tuberculosis treatment in Kandahar Province, Afghanistan, Uncontrolled Clinical StudyVanaf1 sep 2019 → 30 apr 2022
- Treatment of Rifampin-resistsant Tuberculosis with an All-Oral Regimen containing new drugs in Zhytomyr UkraineVanaf1 mrt 2019 → 31 jul 2021
- End TB Clin.Trial Output 2Vanaf1 jun 2016 → 31 aug 2023
- Improving detection of drug-resistant tuberculosis (TB by use of novel phenotypic and genotypic testsVanaf1 jan 2013 → Heden
Publicaties
1 - 10 van 15
- Middlebrook 7h11 reduces invalid results and turnaround time of phenotypic drug‑susceptibility testing of M. tuberculosis(2022)
Auteurs: Rupasinghe Arachchige Praharshinie Rupasinghe, Jens Vereecken, Pieter Graulus, Tom Decroo, Elisa Ardizzoni, Cathy Hewison, Dimitri Donchuk, Helena Huerga, Anita Mesic, Leen Rigouts, et al.
Pagina's: 407-411 - Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment(2022)
Auteurs: Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, et al.
- Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests(2021)
Auteurs: Elisa Ardizzoni, E. Ariza, D. Mulengwa, Q. Mpala, R de la Tour, Gugu Maphalala, F. Varaine, Bernhard Kerschberger, Pieter Graulus, A-L Page, et al.
- Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial(2021)
Auteurs: L. Guglielmetti, Elisa Ardizzoni, M. Atger, E. Baudin, E. Berikova, M. Bonnet, E. Chang, Sandrine Cloez, J. M. Coit, J Cox, et al.
- Evaluation of OMNIgene Sputum and ethanol reagent for preservation of sputum prior to Xpert and culture testing in Uganda(2020)
Auteurs: Elisa Ardizzoni, Patrick Orikiriza, Charles Ssuuna, Dan Nyehangane, Mourad Gumsboga, Ivan Mugisha Taremwa, Esther Turyashemererwa, Juliet Mwanga-Amumpaire, Celine Langendorf, Maryline Bonnet
- MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era(2020)
Auteurs: Patrick Beckert, Elisabeth Sanchez-Padilla, Matthias Merker, Viola Dreyer, Thomas Andreas Kohl, Christian Utpatel, Claudio U. Koeser, Ivan Barilar, Nazir Ismail, Shaheed Vally Omar, et al.
- Incremental yield of including Determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya(2017)
Auteurs: Helena Huerga, Gabriella Ferlazzo, Paolo Bevilacqua, B Kirubi, Elisa Ardizzoni, Stephen Wanjala, Joseph Sitienei, Maryline Bonnet
- Nontuberculous Mycobacteria infections at a provincial reference hospital, Cambodia(2017)
Auteurs: Maryline Bonnet, Kim Chamroeun San, Yati Pho, Chandara Sok, Jean-Philippe Dousset, William Brant, Northan Hurtado, Khun Kim Eam, Elisa Ardizzoni, Seiha Heng, et al.
Pagina's: 1139-1147 - Correlatie tussen verschillende fenotypische methodes voor het bepalen van resistentie aan fluroquinolones bij Mycobacterium tuberculosis(2016)
Auteurs: Nele Coeck, Bouke de Jong, Maren Diels, Pim De Rijk, Elisa Ardizzoni, Armand Van Deun, Leen Rigouts
Pagina's: 1233-1240 - Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis(2015)
Auteurs: A-L Page, Elisa Ardizzoni, M Lassovsky, B Kirubi, D Bichkova, A Pedrotta, C Lastrucci, R de la Tour, M. Bonnet, F. Varaine
Pagina's: 1078-1083, i-iii